Johnson & Johnson reported first-quarter earnings that beat ​Wall Street expectations on Tuesday and raised its full-year forecast, as strong demand for cancer ‌drug Darzalex and psoriasis treatment Tremfya more than offset a steep falloff in sales of its blockbuster autoimmune drug Stelara.